60 DEGREES PHARMACEUTICALS, INC. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
60 Degrees Pharmaceuticals announced October 6, 2026 that its randomized Phase IIb/III study of tafenoquine for severe hospitalized babesiosis will conclude enrollment at 30 subjects (vs. originally planned 33). A Data Safety Monitoring Board interim analysis on October 1, 2026 found no safety signals and recommended completing the study as planned. The company will unblind results in January 2027 and seek a pre-sNDA meeting with FDA that same month to discuss regulatory pathway (potential accelerated approval via refractory-disease cases and expanded-access data if the hospital study misses primary endpoint, or regular sNDA if positive). Expanded-access study shows 3 of first 5 enrolled patients achieved molecular cure per NAT testing.
Why this rating
For a $3.3M market-cap biotech, a pivotal clinical readout in 4 months on its sole clinical-stage asset is highly significant. Positive data could enable FDA filing and potential babesiosis label expansion. Multiple viable regulatory pathways reduce risk. However, trial is small (N=30) and babesiosis is niche market; upside capped.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.